ClinicalTrials.gg
RecruitingNCT07265297Updated Dec 4, 2025

Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis

A Phase 3 interventional study of Hydrochloroquine and Placebo in Steatohepatitis, Nonalcoholic, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by National Taiwan University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan — 12 open to participants now, 16 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Taiwan.

Planned enrollment
19th of 41
210 · median 145
Started
2025
with 3 others
Phase 3
11 of 48
5 open now
Primary completion
2030-12
later than 15 of 15 live
Registered
47th of 48
by date
Lead sponsor
5 of 48
National Taiwan University Hospital

Among the 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan, this one is the 19th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 15 of the 15 other live ones, and was the 47th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

12 of the 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug hydroxychloroquine works to treat steatohepatitis in adults. It will also learn about the safety of drug hydroxychloroquine. The main questions it aims to answer are:

Does drug hydroxychloroquine improve steatohepatitis? What medical problems do participants have when taking drug hydroxychloroquine? Researchers will compare drug hydroxychloroquine to a placebo (a look-alike substance that contains no drug) to see if drug hydroxychloroquine works to treat steatohepatitis.

Participants will:

Take drug hydroxychloroquine 400mg or hydroxychloroquine 200mg or placebo every day for 12 months Visit the clinic once every 3 months for checkups and tests

03

Conditions studied

  • Steatohepatitis, Nonalcoholic

Keywords

  • steatohepatitis
  • fatty liver
  • Hydroxychloroquine
  • Drug repurposing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be at least 18 years old.
  2. Participants must be able to return for scheduled follow-up visits during specific time points within the 12-month study period.
  3. Diagnosis of fatty liver confirmed by abdominal ultrasound or magnetic resonance imaging (MRI).
  4. Evidence of hepatic inflammation for more than three months, indicated by (ALT) > 41 IU/L.

Exclusion criteria

Exclusion Criteria:

  1. Participants younger than 18 years old.
  2. Pregnant or breastfeeding women.
  3. Active viral hepatitis, determined by serum or viral load.
  4. Currently taking hydroxychloroquine (HCQ) for other medical conditions or indications.
  5. Known history of or severe adverse drug reaction to HCQ.
  6. Presence of retinal maculopathy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    HCQ 400mg

    Drug: Hydrochloroquine

  • Experimental
    HCQ 200mg

    Drug: Hydrochloroquine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHydrochloroquine

    Recruit 210 subjects and randomly allocate them in 1:1:1 manners to three groups: HCQ 400 mg/d, HCQ 200mg/d and placebo. All subjects will receive HCQ and / or placebo for one year.

  • DrugPlacebo

    Recruit 210 subjects and randomly allocate them in 1:1:1 manners to three groups: HCQ 400 mg/d, HCQ 200mg/d and placebo. All subjects will receive HCQ and / or placebo for one year.

06

What researchers measure

Primary outcomes

  1. serum ALT

    Time frame: Every 3 months, for 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2030, 64 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 4, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265297
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Aug 12, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Dec 4, 2025

Study contacts

Tsai, Doctor
Contact
fengchiaotsai@ntu.edu.tw
88623123456 ext. 288320

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion